Histamine2 (H2) - receptor antagonists are widely prescribed for a variety of acid-mediated gastrointestinal disorders.
The objective of the present study was to quantify the frequency of inappropriate H2-receptor antagonist use and its economic impact in patients who were admitted to a critical care bed at our hospital and followed as outpatients for I year.
Eighty-eight (72%) of 123 patients admitted to the coronary care unit (CCU) or the intensive care unit over a 14-day period received H2-receptor antagonists.
Forty-five (51%) of the 88 patients did not have a documented indication for H2-receptor antagonist therapy.
Most of the patients without indications were admitted to the CCU for cardiac diagnoses.
Thirty-eight patients (43%) were discharged on oral H2-receptor antagonist therapy.
Twenty (53%) of the 38 patients had no documented indication for therapy ; 17 of these patients continued H2-receptor antagonist therapy for 1 year, whereas the remaining 3 patients received therapy for 1,2, and 3 months, respectively.
The cost of therapy for the 45 patients receiving inappropriate therapy during hospitalization was $5,084.31.
Outpatient costs for the 20 patients remaining on inappropriate therapy was $8,619.75.
The total cost of inappropriate therapy was $13,704.06.
If data collected during this 2-week period were extrapolated to 1 year, the projected annual cost of inappropriate therapy would be $356,305.56. (...)
Mots-clés Pascal : Récepteur histaminergique H2, Antiacide, Antiulcéreux, Antagoniste, Antihistaminique, Analyse avantage coût, Analyse coût efficacité, Efficacité traitement, Homme, Economie santé, Etude critique, Utilisation, Hôpital, Unité soin intensif, Analyse économique
Mots-clés Pascal anglais : H2 Histamine receptor, Antiacid, Antiulcer agent, Antagonist, Antihistaminic, Cost benefit analysis, Cost efficiency analysis, Treatment efficiency, Human, Health economy, Critical study, Use, Hospital, Intensive care unit, Economic analysis
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0053555
Code Inist : 002B30A01C. Création : 14/05/1998.